Biomerica (NASDAQ:BMRA) Given a $6.00 Price Target by B. Riley Analysts
B. Riley set a $6.00 target price on Biomerica (NASDAQ:BMRA) in a research report released on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock.
BMRA traded down $0.12 during trading on Tuesday, hitting $2.88. The stock had a trading volume of 34,036 shares, compared to its average volume of 28,147. The firm has a market capitalization of $28.13 million, a P/E ratio of -11.06 and a beta of 1.45. Biomerica has a twelve month low of $1.60 and a twelve month high of $3.78. The company’s 50-day moving average price is $3.13 and its 200 day moving average price is $2.67.
Biomerica (NASDAQ:BMRA) last released its earnings results on Friday, August 30th. The company reported ($0.08) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). The company had revenue of $1.17 million during the quarter, compared to analysts’ expectations of $1.36 million. Biomerica had a negative net margin of 46.01% and a negative return on equity of 58.31%. As a group, analysts predict that Biomerica will post -0.34 earnings per share for the current year.
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Recommended Story: How to interpret the current ratio
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.